Does surfactant therapy prolong dying? Age at in-hospital death of extremely premature babies.
We reviewed medical records of inborn babies of < 30 gestational weeks who died before hospital discharge to identify the cause of death and age at death. We compared all surfactant-treated babies born during the first 19 months of our experience in a phase III trial of exogenous surfactant prophylaxis of respiratory distress syndrome with all untreated babies born during the 19 months immediately preceding the surfactant trial. The two groups were virtually identical in birth weight and gestational age. Mortality in all gestational age groups declined by half after the initiation of surfactant treatment. The mean age at death did not change significantly. Cases of early or late mortality did not change between the two periods. Exogenous surfactant prophylaxis does not significantly prolong the lives of extremely premature babies who are destined to die before hospital discharge.
Coulter
D M
DM
Department of Pediatrics, LDS Hospital, Salt Lake City, UT 84143, USA.
Jung
A L
AL
D016001:Confidence Intervals; D005865:Gestational Age; D017052:Hospital Mortality; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000401:mortality; D013501:Surface-Active Agents / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
D013501:Surface-Active Agents